Kirkland & Ellis LLP advised New York-based Acorda Therapeutics, Inc. (Nasdaq: ACOR) on its agreement to acquire Finland-based Biotie Therapies Corp. (Nasdaq: BITI) for approximately $363 million. Acorda will obtain worldwide rights to tozadenant, an oral adenosine A2a receptor antagonist currently in Phase 3 development in Parkinson’s disease. This is the first acquisition of a Finnish public company listed in both Helsinki and New York. The full release is available here.
The Kirkland team was led by corporate partners Daniel Wolf and Joshua Zachariah and associates Will Boothby and Silviu Pitis.